[CAS NO. 1037184-44-3] YK-4-279
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1037184-44-3]
Store
Catalog
SLK-S7679
Brand
Selleck
CAS
1037184-44-3
DESCRIPTION [1037184-44-3]
Overview
| MDL | MFCD18382120 |
|---|---|
| Molecular Weight | 366.20 |
| Molecular Formula | C17H13Cl2NO4 |
| SMILES | O=C1NC2=C(C(Cl)=CC=C2Cl)C1(O)CC(C3=CC=C(OC)C=C3)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7307 mL | 13.6537 mL | 27.3075 mL |
| 5 mM | 0.5461 mL | 2.7307 mL | 5.4615 mL |
| 10 mM | 0.2731 mL | 1.3654 mL | 2.7307 mL |
| 50 mM | 0.0546 mL | 0.2731 mL | 0.5461 mL |
Description
YK-4-279 is a potent inhibitor of binding to .
Targets
| RHA [1] |
In vitro
YK-4-279 eliminates cyclin D levels by blocking the interaction of EWS-FLI1 with RHA in EWS-FLI1-containing TC32 cells. YK-4-279 also specifically inhibits ESFT cell growth and induces apoptosis. YK-4-279 also inhibits ERG and ETV1 biological activity in fusion-positive prostate cancer cells, and further decreases cell motility and invasion.
In vivo
In vivo, YK-4-279 (1.5 mg/dose i.p.) inhibits the growth of ESFT xenograft tumors. In mouse model, YK-4-279 selectively prevents prostate cancer growth and metastasis in fusion-positive LNCaP-luc-M6 tumors.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.